Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to LAG3/CD223 protein is a common target in medicine.

LAG-3 (lymphocyte-activated gene-3, also known as CD223) is an inhibitory immune checkpoint molecule highly expressed on activated T cells, and it is a transmembrane protein. The LAG-3 protein consists of four extracellular immunoglobulin-like domains (D1-D4) with high homology with CD4. The LAG-3 protein consists of four extracellular domains, D1 – D4, similar to Ig, where, both D1 and D2 are involved in the FGL 1 – LAG-3 interaction.

LAG-3 intracellular directly suppresses downstream signaling of TCR-CD3 complex by its unique "KIEELE" sequence, repetitive glutamate-proline (EP) repeats and serine phosphorylation sites, exerting a non-redundant immunosuppressive function FGL 1 interacts with LAG-3 in an MHC-II-independent manner, involving the FGL 1 fibrinogen-like domain and the LAG-3 D1 D2 domain. The cytoplasmic tail of LAG-3 mediates the negative signaling in the cell. When LAG-3 binds to its ligand, it transmits inhibitory signals through its cytoplasmic domain, inhibiting the initial steps of the T-cell receptor (TCR) pathway, preventing the activation of transcription factors ( NFAT), and leading to a decrease in cytokine production and T-cell proliferation.

At present, various drugs targeting LAG3/CD223 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. LAG3/CD223 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, LAG3/CD223 protein products are also essential. Alpha Lifetech can provide LAG3/CD223 corresponding products and help each customer's research and development. Alpha Lifetech focuses on high-precision detection development and validation services to support drug screening and biosimilar discovery. Our detection methods, including ELISA, cell-based functional testing, and flow cytometry, have undergone rigorous sensitivity, specificity, and reproducibility testing. In addition to testing and development, our team also provides data analysis, scheme optimization, and cross-species reactivity testing to ensure reliable results.